by Randi Love | Nov 28, 2022
Antidepressant drugs have been on the market since the 1950s, but Axsome Therapeutics is betting its new treatment will have a major impact on patients and doctors. In late October, the company launched Auvelity, a prescription-only, fast-acting, oral medication aimed...
by Randi Love | Nov 4, 2022
Axsome Therapeutics Inc. has two central nervous system products on the market that have the industry buzzing around the small biotech company. The drugs Sunosi, a product that promotes wakefulness in patients with sleep apnea, and Auvelity, a fast-acting novel...
by Randi Love | Oct 8, 2022
Axsome Therapeutics Inc. plans to resubmit its New Drug Application for its product which is designed to aid in the treatment of acute migraines to the U.S. Food and Drug Administration, according to a news release. On Sept. 29, the company said its resubmission of...
Welcome to Investment Journal, a site covering the world of business right from Times Square. The site is produced by reporters at the New York City News Service and the Craig Newmark Graduate School of Journalism at CUNY. Email your comments to greg.david@journalism.cuny.edu.